Omeros Corporation OMER
NASDAQ · United States · Health Technology
$19.11+0.07 (+0.37%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.